Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS: We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS: Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS: Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition. FUNDING: This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the presence of CD8 + PD-1 hi T cells in the tumors of patients with melanoma and patients with NSCLC prior to anti-PD-1 administration was predictive of treatment response and correlated with overall survival (146, 147).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Cited by
Items 301–400 of 528
O’Meara, C. H., Jafri, Z., & Khachigian, L. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411695 · Cited by 18
Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma
Vargas, G. M., Shafique, N., Xu, X., & Karakousis, G. C. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2312102 · Cited by 20
Patel, T., Cunningham, A., Holland, M., Daley, J. F., Lazo, S., Hodi, F. S., & Severgnini, M. (2017) · Cytotechnology · doi:10.1007/s10616-017-0106-3 · Cited by 16
Kim, S.-H., Singh, R., Han, C., Cho, E., Kim, Y. I., Lee, D. G., Kim, Y. H., Kim, S. S., Shin, D. H., You, H. J., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00533-3 · Cited by 15
Cancer immunotherapy: Breakthrough or “deja vu, all over again”?
Sell, S. (2017) · Tumor Biology · doi:10.1177/1010428317707764 · Cited by 19
Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival
Karstens, K.-F., Kempski, J., Giannou, A. D., Pelczar, P., Steglich, B., Steurer, S. A., Freiwald, E., Woestemeier, A., Konczalla, L., Tachezy, M., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02517-8 · Cited by 17
Liu, D., Xiao, H., Xiang, Y., Zhong, D., Liu, Y., Wang, Y., & Zhang, W. (2025) · Journal of Cancer · doi:10.7150/jca.108163 · Cited by 18
Hunt, K. S., & Alspach, E. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0005 · Cited by 19
Individually addressable and dynamic DNA gates for multiplexed cell sorting
Dahotre, S. N., Chang, D. Y., Wieland, A., Stammen, S. R., & Kwong, G. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714820115 · Cited by 16
Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M. S., Ferrone, S., Formenti, S. C., Gajewski, T. F., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1979-z · Cited by 16
Prognostic Biomarkers for Melanoma Immunotherapy
Twitty, C., Huppert, L. A., & DAUD, A. I. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0886-z · Cited by 16
Self-citationOrganized immune cell interactions within tumors sustain a productive T-cell response
Cardenas, M. A., Prokhnevska, N., & Kissick, H. T. (2020) · International Immunology · doi:10.1093/intimm/dxaa057 · Cited by 14
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15
Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
Yang, H., Yang, C., Wu, C., Wang, L.-J., & Lu, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133162 · Cited by 16
Mahuron, K. M., Shahid, O., Sao, P., Wu, C., Haugh, A. M., Huppert, L. A., Levine, L. S., Lowe, M. M., Alvarado, M., Micu, M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-23-3918 · Cited by 13
Self-citationStukalin, I., Navani, V., Gupta, M., Ruan, Y., Boyne, D. J., O'Sullivan, D. E., Meyers, D. E., Goutam, S., Sander, M., Ewanchuk, B. W., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad073 · Cited by 17
Tarhini, A. A., Eroglu, Z., Eljilany, I., Zager, J. S., González, R., Sarnaik, A. A., Cruse, C. W., Khushalani, N. I., Aquino, D. B. D., Abraham, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2768 · Cited by 19
The function and regulation of PD-L1 in immunotherapy
Guo, L., Lin, Y., & Kwok, H. F. (2017) · ADMET & DMPK · doi:10.5599/admet.5.3.442 · Cited by 16
Chen, W., Fung, A. S., McIntyre, J. B., Simpson, R. H. W., Afzal, A. R., Hao, D., & Lau, H. (2021) · Clinical and investigative medicine · doi:10.25011/cim.v44i1.35218 · Cited by 14
Towards In Silico Prediction of the Immune-Checkpoint Blockade Response
Chen, K., Ye, H., Lu, X., Sun, B., & Liu, Q. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.002 · Cited by 14
Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers
Oglesby, A., Algazi, A. P., & DAUD, A. I. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00452-8 · Cited by 15
Self-citationTreatment options after first-line immunotherapy in metastatic NSCLC
Santos, E. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1738930 · Cited by 14
PD-1 , CTLA4 , PD-L1 and PD-L2 DNA Methylation in Papillary Thyroid Carcinoma
de Vos, L., Dietrich, J., Strieth, S., Bootz, F., Dietrich, D., & Franzen, A. (2020) · Immunotherapy · doi:10.2217/imt-2020-0037 · Cited by 15
Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma
Lv, L., Wei, Q., Wang, Z., Zhao, Y., Chen, N., & Yi, Q. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.690186 · Cited by 15
Yang, Z., Zheng, Y., Wu, H., Xie, H., Zhao, J., Chen, Z., Li, L., Yue, X., Zhao, B., & Bian, E. (2023) · Human Genomics · doi:10.1186/s40246-023-00480-w · Cited by 14
Vu, T. T., Kim, K., Manna, M., Thomas, J. W., Remaily, B., Montgomery, E. J., Costa, T., Granchie, L., Xie, Z., Guo, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107048 · Cited by 14
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes
Akinjiyan, F. A., Nassief, G., Phillipps, J., Adeyelu, T. T., Elliott, A., Abdulla, F. R., Zhou, A. Y., Souroullas, G. P., Kim, K. B., Vanderwalde, A. M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54136-3 · Cited by 14
Assessing Treatment Benefit in Immuno-oncology
Buyse, M. E., Saad, E. D., Burzykowski, T., & Péron, J. (2020) · Statistics in Biosciences · doi:10.1007/s12561-020-09268-1 · Cited by 13
Kwiecień, I., Rutkowska, E., Polubiec-Kownacka, M., Raniszewska, A., Rzepecki, P., & Domagala-Kulawik, J. J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1103 · Cited by 13
Ma, R., Qu, X., Che, X., Yang, B., Li, C., Hou, K., Guo, T., Xiao, J., & Liu, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s304297 · Cited by 14
Tong, Q., Li, D., Yin, Y., Cheng, L., & Ouyang, S. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s401430 · Cited by 14
SPICA: Swiss portal for immune cell analysis
Andreatta, M., David, F., Iseli, C., Guex, N., & Carmona, S. (2021) · Nucleic Acids Res. · doi:10.1093/nar/gkab1055 · Cited by 12
Lim, S. Y., & Rizos, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9757-4 · Cited by 13
Edner, N. M., Ntavli, E., Petersone, L., Wang, C. J., Fabri, A., Kogimtzis, A., Ovcinnikovs, V., Ross, E. M., Heuts, F. W. H., Elfaki, Y., et al. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad001 · Cited by 13
Contemporary Approaches to Immunotherapy of Solid Tumors
Kuznetsova, A. V., Glukhova, K. А., Попова, О. П., Beletsky, I. P., & Aa, I. (2024) · Cancers · doi:10.3390/cancers16122270 · Cited by 14
STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity
Tan, J., Egelston, C. A., Guo, W., Stark, J. M., & Lee, P. P. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105035 · Cited by 14
Khunger, A., Piazza, E., Warren, S. E., Smith, T. H., Ren, X., White, A. M., Elliott, N., Cesano, A., Beechem, J., Kirkwood, J. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245287 · Cited by 11
Archetypes of checkpoint-responsive immunity
Im, K. W., Combes, A. J., Spitzer, M. H., Satpathy, A. T., & Krummel, M. F. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.007 · Cited by 15
Self-citationThe potential application of PD-1 blockade therapy for early-stage biliary tract cancer
Umemoto, K., Togashi, Y., Arai, Y., Nakamura, H. K., Takahashi, S., Tanegashima, T., Kato, M., Nishikawa, T., Sugiyama, D., Kojima, M., et al. (2019) · International Immunology · doi:10.1093/intimm/dxz080 · Cited by 13
Back from the dead: TIL apoptosis in cancer immune evasion
Horton, B. L., & Gajewski, T. F. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.483 · Cited by 11
Metabolic predictors of response to immune checkpoint blockade therapy
Shorer, O., & Yizhak, K. (2023) · iScience · doi:10.1016/j.isci.2023.108188 · Cited by 11
Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?
Pu, X., Chao, G., Dong, L., & Chang, P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1739794 · Cited by 11
Resident Memory T Cells in the Tumor Microenvironment
Williams, J. B., & Kupper, T. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_3 · Cited by 12
Jiang, C., Cai, X., Zhang, H., Xia, X., Zhang, B., & Xia, L. (2017) · Journal of Cancer · doi:10.7150/jca.21414 · Cited by 11
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Schmid, S., Mauti, L. A., Friedlaender, A., Blum, V., Rothschild, S. I., Bouchaab, H., Frösch, P., Britschgi, C., König, D., Wannesson, L., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02565-0 · Cited by 12
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Levine, L. S., Mahuron, K. M., Tsai, K. K., Wu, C., Mattis, D. M., Pauli, M. L., Oglesby, A., Lee, J., Spitzer, M. H., Krummel, M. F., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08648-7 · Cited by 13
Self-citationMechanism of resistance to immune checkpoint inhibitors
Pandey, M. R., & Ernstoff, M. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.015 · Cited by 11
Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
Boehm, D. T., Landreth, K. M., Sen-Kilic, E., Lee, K. S., Misra, B., Bobbala, S. K. R., Damron, F. H., & Liu, T. W. B. (2025) · Scientific Reports · doi:10.1038/s41598-025-89930-0 · Cited by 12
Liu, S., Liang, Z., Zhu, L., Zheng, Y., Yu, H., Ye, S., Liang, T., Huang, L., Ouyang, J., Cao, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012259 · Cited by 9
Slingerland, N., Runderkamp, E., & Thommen, D. S. (2026) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082724-123843 · Cited by 12
Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
Chen, X., Kou, L., Xie, X., Su, S., Li, J., & Li, Y. (2024) · Immunology · doi:10.1111/imm.13751 · Cited by 10
Khojandi, N., Connelly, L., Piening, A., Hoft, S. G., Pherson, M., Donlin, M. J., DiPaolo, R. J., & Teague, R. M. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03263-9 · Cited by 11
Falkenius, J., Johansson, H., Tuominen, R., Stolt, M. F., Hansson, J., & Brage, S. E. (2017) · BMC Cancer · doi:10.1186/s12885-017-3577-x · Cited by 10
Tan, A. R., O’Shaughnessy, J., Cao, S., Ahn, S., & Yi, J. S. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07009-8 · Cited by 8
Ghosh, C. C., Cournoyer, L., Liu, Y., Ballarin, A., Layman, I. B., LaPorte, J. P., Morrissey, M., Fraser, K., Perati, S., Cox, B. F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008837 · Cited by 8
Im, K. W., Huppert, L. A., Malevanchik, L., Rugo, H. S., Combes, A. J., Campbell, M. J., Krummel, M. F., & Melisko, M. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00526-1 · Cited by 11
Self-citationImmune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling
Wu, L., Park, S.-H., Jakobsson, H., Shackleton, M. J., & Möller, A. (2024) · Cancers · doi:10.3390/cancers16111950 · Cited by 10
Desîlets, A., Pinheiro, G., Belkaïd, W., Salko, O., Malo, J., Zarour, E., Jouquan, A., Thibaudeau, A.-J., Nolin, M., Stagg, J., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100737 · Cited by 11
Cuevas, E. S., Mouret, S., Vayssière, G., Kerboua, S., Girard, P., Molens, J., Manceau, M., Charles, J., Saas, P., & Aspord, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1507938 · Cited by 8
Chen, Z., Chen, Q., Li, S., Tu, S., Chen, Q., & Wang, A. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6915 · Cited by 8
Brennan, M., DeBruin, D., Nwokolo, C., Hunt, K. S., Piening, A., Donlin, M. J., Ferris, S. T., Teague, R. M., DiPaolo, R. J., & Alspach, E. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0826 · Cited by 11
Loo, K. L., Gauvin, G., Soliman, I., Renzetti, M., Deng, M., Ross, E. A., Luo, B., Wu, H. G., Reddy, S. S., Olszanski, A. J., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12909 · Cited by 8
Self-citationFingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Ali, O. H., Berner, F., Ackermann, C. J., Ring, S. S., Moulin, A., Müller, J., Markert, E., Pop, O. T., Müller, S., Diem, S., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02693-7 · Cited by 8
Mou, W., Zhu, L., Yang, T., Lin, A.-Q., Lyu, Q., Guo, L.-L., Liu, Z.-B., Cheng, Q., Zhang, J., & Luo, P. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02651-6 · Cited by 7
Garg, T., Weiss, C. R., & Sheth, R. A. (2022) · Cancers · doi:10.3390/cancers14153628 · Cited by 8
Hilakivi-Clarke, L. A., Verma, V., McDermott, M., Koak, P., & Andrade, F. D. O. (2022) · Frontiers in Microbiomes · doi:10.3389/frmbi.2022.1049688 · Cited by 7
Trial Design for Cancer Immunotherapy: A Methodological Toolkit
Saad, E. D., Coart, E., Deltuvaite‐Thomas, V., Barrado, L. G., Burzykowski, T., & Buyse, M. E. (2023) · Cancers · doi:10.3390/cancers15184669 · Cited by 11
Hoeijmakers, Y. M., Gorris, M. A. J., Sweep, F. C. G. J., Bulten, J., Eysbouts, Y. K., Massuger, L. F. A. G., Ottevanger, P. B., & de Vries, J. I. J. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.11.005 · Cited by 7
Zlotnik, O., Krzywoń, L., Kalil, J., Bloom, J., Tubi, I. A., Lazaris, A., & Metrakos, P. P. (2023) · Cancers · doi:10.3390/cancers15215210 · Cited by 10
Zhang, G., Tu, J., Zhang, Y., He, J., Peng, G., Fan, Q., Zhang, Y., Zhang, M., Tan, H., Xu, Y., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102620 · Cited by 8
Shi, A., Yan, M., Pang, B., Pang, L., Wang, Y., Lan, Y., Zhang, X., Xu, J., Ping, Y., & Hu, J. R. (2023) · BMC Immunology · doi:10.1186/s12865-023-00587-8 · Cited by 8
Laubli, H. P., Dirnhofer, S., & Zippelius, A. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2435-9 · Cited by 6
Yeo, C. D., Kim, I. K., Ban, W. H., Kang, H. S., Kim, J. W., Kim, S. J., Park, J. Y., & Lee, S. H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.05.02 · Cited by 7
Sung, J., Park, D.-W., & Lee, S. H. (2022) · Biomedicines · doi:10.3390/biomedicines10092109 · Cited by 9
Repáraz, D., Ruiz, M., Silva, L., Aparicio, B., Egea, J., Guruceaga, E., Ajona, D., Senent, Y., Conde, E., Navarro, F. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991311 · Cited by 5
Homicskó, K., Duraiswamy, J., Doucey, M., & Coukos, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2868 · Cited by 6
Loo, K. L., & DAUD, A. I. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000238 · Cited by 6
Self-citationCharacterization of tumour-infiltrating lymphocytes in a tumour rejection cynomolgus macaque model
Satooka, H., Ishigaki, H., Todo, K., Terada, K., Agata, Y., Itoh, Y., Ogasawara, K., & Hirata, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-65488-x · Cited by 6
VISTA, PDL-L1, and BRAF—A Review of New and Old Markers in the Prognosis of Melanoma
Tinca, A. C., Cocuz, I. G., Șincu, M. C., Niculescu, R., Sabău, A. H., Chiorean, D. M., Cozac-Szőke, A. R., & Cotoi, O. S. (2022) · Medicina · doi:10.3390/medicina58010074 · Cited by 7
Trono, P., Sistigu, A., Palermo, B., Ciliberto, G., & Nisticò, P. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170068 · Cited by 7
Exhaustion of T cells after renal transplantation
Wang, X., Zhang, J., Zhong, P., & Wei, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418238 · Cited by 10
Lee, S., Yun, J. S., Kim, Y. J., Jeong, S., Noh, J. E., Kim, H.-O., Cho, H.-J., Park, C., Oh, I., & Cho, J.-H. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01448-7 · Cited by 8
Sun, Q., Gao, R., Lin, Y., Zhou, X., Wang, T., & He, J. (2024) · MedComm · doi:10.1002/mco2.563 · Cited by 6
Martínez-Vila, C., González‐Navarro, E. A., Teixidó, C., Martin, R., Aya, F., Juan, M., & Arance, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179506 · Cited by 5
Duruisseaux, M., Lize-Dufranc, C., Badoual, C., & Bibeau, F. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.016 · Cited by 5
The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1
Wilmott, J. S., Rizos, H., Scolyer, R. A., & Long, G. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0669 · Cited by 5
Precision therapy in advanced urothelial cancer
Schiff, J. P., Barata, P. C., Yu, E. Y., & Grivas, P. D. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1582298 · Cited by 5
Singh, P., SOUZA, P. D., Scott, K. F., Hall, B. M., Verma, N. D., Becker, T. M., Toh, J. W. T., Sajinovic, M., & Spring, K. J. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0032-9 · Cited by 6
Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma
Kim, D., Chu, S. H., Khan, A. U., Compres, E. V., Zhang, H., Gerami, P., & Wayne, J. D. (2021) · Archives of Dermatological Research · doi:10.1007/s00403-021-02229-8 · Cited by 5
Miyamoto, K., Hayabuchi, H., Tokifuji, Y., Ando, M., Onishi, N., Okamura, T., Yoshimura, A., & Chikuma, S. (2022) · International Immunology · doi:10.1093/intimm/dxac035 · Cited by 6
Indini, A., Lombardo, M., Sidoni, A., Gianatti, A., Mandalà, M., & Massi, D. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000375 · Cited by 5
Nagasaka, M., Abdallah, N. H., Crosby, M. A., Thummala, N., Patel, D., Wozniak, A. J., Gadgeel, S. M., Abrams, J., & Sukari, A. W. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s219886 · Cited by 6
Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma
Huppert, L. A., & DAUD, A. I. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00943 · Cited by 5
Self-citationImmunotherapy in gastric cancer with liver metastasis: Challenges and opportunities
Bardakçı, M., & Ergün, Y. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i6.1513 · Cited by 5
The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma
Vestergaard, C. D., Ellebæk, E., Borch, T. H., Donia, M., & Svane, I. M. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00969-1 · Cited by 7
A Bayesian phase I–II clinical trial design to find the biological optimal dose on drug combination
Wang, Z., Zhang, J., Xia, T., He, R., & Yan, F. (2023) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2023.2236208 · Cited by 4
Cheng, Z., Zeng, T., Yang, G., Liu, D., Zheng, Z., & Yuan, Z. (2023) · Liver Cancer · doi:10.1159/000530273 · Cited by 5
Creasy, C. A., Forget, M., Singh, G., Tapia, C., Xu, M., Stephen, B., Sabir, S. H., Meric‐Bernstam, F., Haymaker, C., Bernatchez, C., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201948217 · Cited by 4
Ying, H., Lin, A., Liang, J., Zhang, J., & Luo, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.629330 · Cited by 5
Qi, Z., Xu, Z., Zhang, L., Zou, Y., Yan, W., Li, C., Liu, N., & Wu, H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.17.343608 · Cited by 4
Metadata
- Authors
- Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., Algazi, A. P., Pampaloni, M. H., Lobach, I. V., Hwang, J., Pierce, R. H., Gratz, I. K., Krummel, M. F., & Rosenblum, M. D.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- University of Salzburg (AT)
- Corresponding author
- Rosenblum, Michael D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-15
- Volume
- 126
- Issue
- 9
- Pages
- 3447-3452
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5004965
- OpenAlex
- W2512255557
- Cited by
- 525
- References
- 23
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 37 · 2023: 47 · 2022: 51 · 2021: 55 · 2020: 89 · 2019: 61 · 2018: 71 · 2017: 64 · 2016: 5
- FWCI
- 36.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- International Business Machines Corporation
- National Institutes of Health (1dp2ar068130-01)
- University of California, San Francisco
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (DP2-AR068130, R21AR066821, K08AR062064)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, anti-PD-1 therapy, immune checkpoint blockade, tumor immune profiling, CD8+ T cell exhaustion, tumor-infiltrating lymphocytes, predictive biomarkers, treatment response prediction, progression-free survival, regulatory T cells
- MeSH terms
- Biopsy, Female, Flow Cytometry, Humans, Immune System, Lymphocyte Activation, Male, Melanoma, Neoplasm Metastasis, Phenotype, Skin Neoplasms, Cohort Studies, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Tumor Microenvironment, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.